Occam’s Global Tech Practice Continues to Expand, Placing Daniel Delubac as COO & CTO at Chemify
Chemify, a Blue Yard and Triatomic investment, leverages an innovative platform combining sophisticated robotics, software, and data science to enable a comprehensive digitization of the known and imagined universe of chemicals as the basis for their sophisticated refinement and manufacturing. The platform has myriad applications including specialty chemicals, therapeutics, and AgTech.
While still an amorphous seed-stage company in late 2022, Occam recruited Daniel Delubac, PhD as COO & CTO. Delubac is a technologist and engineer well-versed at conjoining AI, robotics, automation, and biology in the service of developing better therapeutics (Xilis) and diagnostics (Freenome). Key to his success in the role at Chemify will be his almost mystical ability to transmute visionary cutting-edge science into reality at scale. He is a powerful complement to founding scientific CEO Lee Cronin and a catalytic force in his own right. Shortly after joining, Chemify was able to close a substantive A round.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.